LONG MINI-FUTURE - ELI LILLY & CO | Delayed Deutsche Boerse AG 19:01:49 21/06/2024 BST | ||
| 51.94 EUR | +0.76% |
|
| Current month | +15.20% | ||
| 1 month | +23.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 51.94 | +0.76% |
| 20/06/24 | 51.55 | -1.57% |
| 19/06/24 | 52.37 | +1.04% |
| 18/06/24 | 51.83 | -0.56% |
| 17/06/24 | 52.12 | +1.50% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 07:01 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6E8E |
| ISIN | DE000VU6E8E3 |
| Date issued | 18/04/2023 |
| Strike | 329.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.9 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 53.03 € |
|---|---|
| Lowest since issue | 6.19 € |
| Spread | 0.03 € |
| Spread % | 0.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Certificates
- Certificat
